CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong · Delayed Price · Currency is HKD 12.61
-0.82 (-6.11%)
Sep 10, 2026, 1:49 PM HKT
HKG:2171 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 136.62 | 125.66 | 39.43 | - | - | 25.81 | |
Revenue Growth | 62.55% | 218.74% | - | - | - | - |
Cost of Revenue | 44.02 | 45.71 | 24.68 | - | - | - |
Gross Profit | 92.6 | 79.95 | 14.75 | - | - | 25.81 |
Selling, General & Admin | 78.26 | 71.81 | 162.84 | 133.31 | 136.61 | 126.52 |
Research & Development | 245.93 | 243.38 | 463.74 | 660.04 | 679.49 | 501.03 |
Other Operating Expenses | -11.18 | -7.35 | -49.62 | -8.3 | -10.45 | -14.34 |
Operating Expenses | 313.01 | 307.84 | 576.97 | 785.05 | 805.65 | 613.21 |
Operating Income | -220.41 | -227.9 | -562.22 | -785.05 | -805.65 | -587.4 |
Interest Expense | -8.04 | -6.9 | -5.71 | -4.66 | -15.52 | -10.87 |
Interest & Investment Income | 13.75 | 14.81 | 41.92 | 72.79 | 27.57 | 9.61 |
Currency Exchange Gain (Loss) | 120.85 | 121.5 | -82.24 | -30.47 | -97.35 | 7.45 |
Other Non Operating Income (Expenses) | - | - | - | - | - | -4,156 |
EBT Excluding Unusual Items | -93.85 | -98.49 | -608.26 | -747.39 | -890.95 | -4,737 |
Gain (Loss) on Sale of Assets | -4.42 | -4.42 | -0.45 | - | - | - |
Asset Writedown | - | - | -189.08 | - | - | - |
Pretax Income | -98.26 | -102.91 | -797.79 | -747.39 | -890.95 | -4,737 |
Income Tax Expense | - | - | 0.35 | 0.41 | 1.3 | 7.65 |
Earnings From Continuing Operations | -98.26 | -102.91 | -798.13 | -747.79 | -892.25 | -4,744 |
Minority Interest in Earnings | 9.08 | 5.05 | - | - | - | - |
Net Income | -89.18 | -97.86 | -798.13 | -747.79 | -892.25 | -4,744 |
Net Income to Common | -89.18 | -97.86 | -798.13 | -747.79 | -892.25 | -4,744 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 552 | 552 | 553 | 556 | 552 | 387 |
Shares Outstanding (Diluted) | 552 | 552 | 553 | 556 | 552 | 387 |
Shares Change | 0.37% | -0.15% | -0.58% | 0.82% | 42.60% | 95.23% |
EPS (Basic) | -0.16 | -0.18 | -1.44 | -1.34 | -1.62 | -12.26 |
EPS (Diluted) | -0.16 | -0.18 | -1.44 | -1.34 | -1.62 | -12.26 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -175.73 | -242.03 | -427.69 | -463.77 | -778.45 | -688.16 |
Free Cash Flow Per Share | -0.32 | -0.44 | -0.77 | -0.83 | -1.41 | -1.78 |
Gross Margin | 67.78% | 63.62% | 37.41% | - | - | 100.00% |
Operating Margin | -161.33% | -181.36% | -1426.04% | - | - | -2275.59% |
Profit Margin | -65.28% | -77.88% | -2024.43% | - | - | -18379.97% |
Free Cash Flow Margin | -128.63% | -192.60% | -1084.81% | - | - | -2665.95% |
EBITDA | -216.99 | -203.91 | -497.08 | -717.64 | -748.73 | -552.49 |
EBITDA Margin | -158.83% | -162.26% | - | - | - | - |
D&A For EBITDA | 3.42 | 23.99 | 65.14 | 67.41 | 56.92 | 34.91 |
EBIT | -220.41 | -227.9 | -562.22 | -785.05 | -805.65 | -587.4 |
EBIT Margin | -161.33% | -181.36% | - | - | - | - |